This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk20: Good day, ladies and gentlemen, and welcome to the AVID Bioservices Second Quarter Fiscal 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. As a reminder, this conference call may be recorded. I would now like to hand the conference over to Tim Bronze of AVID Investor Relations Group. Please go ahead.
spk19: Thank you. Good afternoon, and thank you for joining us. On today's call, we have Nick Greene, President and CEO, Dan Hart, Chief Financial Officer, and Timothy Compton, Chief Commercial Officer. Today, we will be providing an overview of Abbott Bioservices' contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended October 31, 2020. After our prepared remarks, we will welcome your questions.
spk13: When it comes to ultra-low temperature freezers, your research demands consistent, dependable technology. Meet PHCBI Brand Products VIP Eco. Call your local representative or visit us on the web for more information.
spk18: If you only list your vacation home on Airbnb, you might attract someone looking for a quaint little studio. But if you list it on Vrbo, you'll attract families looking for a bit more and who spend over twice as much more. Your dream guests await. Become a Vrbo host today.
spk19: Before we begin, I'd like to caution that comments made during this conference call today, December 2nd, 2020, will contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning the current belief of the company, which involves a number of assumptions, risks, and uncertainties. Actual results could differ from these statements, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. With that, I will turn the call over to Nick Green, AVID's President and CEO.
spk03: Thank you, Tim, and thank you to everyone who has dialed in and to those who are participating today via webcast. I am pleased to report that the second quarter was highly productive for AVID. From a financial perspective, we again beat revenue expectations. and had a strong showing in other key financial metrics. In business development, we added a new process development customer, as well as another new manufacturing project from an existing customer. The company had a strong operational performance during the quarter, during which we successfully completed our annual maintenance program. More importantly, we finalized our review of expansion options and we look forward to proceeding with this important effort. Tim and I will provide additional details on business development and operations following an overview of our second quarter financial results. And for that, I'll turn the call over to Dan.
spk06: Thank you, Nick. Before I begin, in addition to the brief financial overview I'll provide on the call today, additional details on our second quarter financial results are included in our press release issued prior to this call and in our Form 10-Q, which was filed today with the SEC. I'll now provide an update of our financial results from continuing operations for the second quarter ended October 31, 2020. Revenues for the second quarter of fiscal 21 were $21.1 million, a 15% increase compared to revenues of $18.3 million recorded during the second quarter of fiscal 20. The growth in the number and scope of in-process and or completed manufacturing runs continue to drive our revenue growth. increase utilization, and improve our gross margin. In addition, the increase in manufacturing revenues included recognition of $1.7 million during the quarter from changes in estimated variable revenue consideration as a result of completing performance obligations for certain manufacturing projects, therefore increasing revenue recognized during that period. With an increase in the number of batches manufactured combined with increased utilization of our personnel, facilities, and equipment, Gross margin for the second quarter of fiscal 21 was 30 percent, up significantly compared to a gross margin of 18 percent for the second quarter of fiscal 20. Our gross margin was further strengthened due to the increase in manufacturing revenue discussed previously and increased capacity utilization. Excluding the $1.7 million in additional manufacturing revenue from a change in estimated variable revenue consideration during the quarter, gross margin was approximately 24 percent. still a significant improvement compared to the 18% in the prior year period. Total SG&A expenses for the second quarter of fiscal 21 were $4.2 million, an increase compared to $3.5 million recorded for the second quarter of fiscal 20. The increase in SG&A was primarily due to increases in payroll-related costs, including stock-based compensation. For the second quarter of fiscal 21, the company recorded a consolidated net income attributable to common stockholders of approximately 800,000 or one cent per basic and diluted share. As compared to a consolidated net loss attributable to common stockholders of 1.9 million or three cents per basic diluted share for the second quarter of fiscal 20. We are also pleased to report the company generated cash flow from operating activities of $10 million during the quarter and $8 million year to date. Our cash and cash equivalents as of October 31, 2020 were $35.7 million, up $7.5 million from the end of the first quarter and consistent as compared to the $36.3 million as of the end of the prior fiscal year. Cash for the period remained steady primarily due to revenue growth and expansion in gross margin partially offset by an increase in capital expenditures.
spk14: TeamShares is a creative, unique, open, sharp, supportive, thought-provoking company that really pushes the boundaries beyond the norms of how businesses should be traditionally ran.
spk07: My very first impressions of TeamShares was too good to be true. TeamShares is reimagining small business ownership in America.
spk12: We buy small businesses from retiring owners, and we help convert them to be employee-owned.
spk09: This not only can lead to more profitable companies, but ultimately to more profitable communities and more wealth creation across the country.
spk11: Our long-term mission is to create $10 billion of new wealth for employee owners in America.
spk07: We're looking for talented presidents to help really bring employee ownership to life at our companies.
spk17: So what Drew made at TeamShares was the whole idea of empowering people with their financial future.
spk16: You can collaborate, you can share ideas, and you can maximize the potential across the board.
spk10: TeamShares has businesses in a wide range of different industries, everything from HVAC to architectural design firms. This is an incredible opportunity for the right candidate. We do not need leaders to come in with industry-specific experience. We just need people who have a growth mindset and are ready to learn. We are looking for individuals from a diverse set of backgrounds to bring their experience and help us grow these businesses.
spk08: I think too often we think we have to wait until we're old and gray before we can exercise our experience in ways that really matter to ourselves, our families, and communities. So having that opportunity to learn early in life exponentially grows my capability to have an impact later in life.
spk09: We're looking for talented, empathetic leaders who really know what it's going to take for a company to move from being a good company to an outstanding company.
spk14: TeamShares is a company that includes you in every facet, and that's something that, quite notably, you're just not going to find anywhere else. TeamShares is opportunity, and it's amazing.
spk08: Is this going to be me saying opportunity, opportunity, opportunity over and over and over again?
spk15: An accident can happen to anyone at any time, and you would usually go to a doctor for the treatment, but you are worried if your insurance will cover the cost of the treatment. They will only cover the first visit to the doctor, or maybe some damage to your insured item, but that is not sufficient at all. At Malloy Law Offices, we will not only cover your medical bills, but whatever you are entitled to, and recover the maximum compensation that your case acclaims. Malloy Law Offices, where justice is done right.
spk06: While we are highly optimistic regarding the balance of the year, we must remain mindful of currently unknown challenges that may present as a result of the COVID-19 pandemic or other industry factors. Having said that, based on the strength of the first half of fiscal 21, the current backlog and together with our visibility into customer demand, we are pleased to report that we are increasing our annual revenue guidance for fiscal 21 from between 76 and 81 million to between 84 and 88 million. This concludes my financial overview. I'll now turn the call over to Tim for an update on business development activities and achievements for the quarter. Thanks, Dan. On the heels of a strong first quarter, we continue to expand AVID's customer base and project pipeline. During the second quarter, our business development team signed new orders for 28 million with new and existing customers. including a new process development customer and a new manufacturing project within an existing customer. While we are always pleased to add new companies to our customer list, we are equally happy to expand our relationships with existing customers as their needs grow. With our 21 million in revenue and the signing of new orders totaling 28 million during the period, our backlog at the end of the second quarter of fiscal 2021 grew to 67 million. an increase of 12% compared to 60 million at the end of the first quarter of fiscal 2021. This represents the highest level of backlog AVID has achieved since becoming a pure play CDMO, and we expect to recognize the majority of this over the next 12 months. Finally, I'm happy to report that the business development team continues to operate and engage with both prospective and current customers with no slowdown in our activities. In fact, the number of requests for proposals continues to ramp and the value of our sales pipeline is at an all-time high. Thankfully, we have not experienced any negative business development related interruptions as a result of the pandemic, and we are hopeful that this will continue. This concludes my business development overview, and I'll now hand the call over to Nick.
spk03: Thank you, Tim. During the second quarter, AVID's operations continue to manufacture to plan. As we reported last quarter, we initiated our scheduled annual preventative maintenance shutdown at the end of July, and this was brought to a successful conclusion during the period. As I indicated last quarter, one of my first tasks at AVID was to review the company's expansion plans, as well as other ancillary requirements ahead of making our final decision with respect to the best path forward. We have now completed this review, and I am happy to report that the company is already moving forward with our expansion using a phased approach. We recently developed plans for a two-phase expansion of our Myford facility. The first phase expands the production capacity of our existing Myford North facility by the addition of a second downstream processing suite. The second phase further expands the capacity through the build-out of a second manufacturing train including both upstream and downstream processing suites within Myford South. Due to an anticipated increase in customer demand, we have commenced the first phase of expansion, which we estimate will take approximately 12 to 15 months to complete, at an estimated cost of approximately $15 million. We expect that the first phase of expansion could increase our annual revenue generating capacity by up to $50 million bringing the combined annual revenue generating capacity of our Franklin and Myford North facilities up to $170 million. The decision to commence the second phase of expansion will be dictated by revenue growth and projected customer demand. Based on preliminary conceptual plans, we estimate that the Myford South expansion will take 18 to 24 months to complete, at a cost of approximately $45 to $55 million. We estimate that the addition of the future Myford South facility will increase our annual revenue generating capacity by up to $100 million. To complete these anticipated expansions, we expect to raise external capital at the appropriate time. Accessing the form of capital that we determine is the most appropriate considering the markets available to us and their respective costs of capital. In closing, we are happy to report a very positive quarter during which we achieved strong revenues and margins, beating estimates for both revenue and earnings per share, as well as generating operating cash flow and income from our operations. Further, increasing our backlog from 60 to 67 million while delivering the above is testament to the excellent work of our business development team and the many people behind the scenes that support them. As a result, we have been able to increase guidance and also initiate our expansion plans with the phased approach, which we believe provides capacity well aligned with demand while being cognizant of both time and cost. This concludes my prepared remarks for today, and we can now open up the call for questions. Operator?
spk20: Thank you. To ask a question, you will need to press star then 1 on your telephone. To withdraw your question, please press the pound key. Our first question comes from the line of Matt Hewitt with Craig Hallam Capital Group. Your line is now open.
spk05: Thank you for taking the questions, and congratulations on a really strong quarter. Maybe first up, the vaccines have been hitting the news. I mean, that is... one of the top items that you see these days. But I'm wondering if you could talk a little bit about the market beyond that, beyond vaccines. What are you seeing? What are you hearing from customers as far as maybe capacity constraints within the market? Is that helping drive some business your way? Anything that you could help there?
spk16: You know Liberty Mutual customizes your car insurance, so you only pay for what you need. Like how I customized this scarf. Check out this backpack I made for Marco.
spk14: Only pay for what you need.
spk00: Liberty, Liberty, Liberty, Liberty.
spk03: Tim, do you want to take that?
spk06: Yeah, sure. Thanks, Matt. Thanks for the question. Yeah, as you can imagine, the vaccine market is taking up a significant amount of capacity right now in the marketplace. And so, certainly, we look to take advantage of that, having our available capacity as well as continuing to build and expand our capacity to meet future demands, as Nick just described. So, there likely is a shortfall of capacity out there with the amount of capacity that's being consumed by COVID to date. And it's not looking like that capacity is going away. I mean, there's still a number of vaccines in development, as well as therapeutics. for the COVID-19 as well.
spk05: That's helpful. Thank you. And then obviously with the phased approach for the build-out and the expansion for Miford, I guess what was it as you kind of looked at things, Nick, what was it that drove you to the decision to kind of split things out that way? Is there any way that you can get customers to kind of lock in or maybe even help pay for some of that expansion? And then as you look out to the phase two piece, same thing there. Is there a situation where you could actually have customers prepaying essentially to have access to that capacity?
spk03: Yeah, so to answer both of those questions, Matt, in terms of the phased approach, I guess what we particularly liked about that approach was it has a shorter timeline than doing it all at one go, so that would take us – somewhere between 18 to 24 months to do the full MyFoodSelf expansion. So this brings the available capacity forward, which is a big benefit. It secondly also allows us to reduce the amount of immediate capital requirement. So it's only a $50 million expenditure rather than the sort of 45 to 55 million, maybe somewhere around there. that we would do for the whole expansion of Myford South. And then on top of that, in bringing it forward and at a lower cost, it also enables us to have sort of an interstitial step in terms of our revenue growth capability, adding that 50 million, which in turn obviously allows us to generate some additional profits in the meantime and contribute towards being able to pay for that to some degree, depending on the timing of those revenues. The idea and the concept of getting somebody else to pay or other people to pay, we're very fortunate that we've managed to maintain capacity ahead of demand. I think that's been some foresight within the business to do that. We certainly anticipate continuing to do that so that our clients know that as they are successful, we can continue to meet their requirements. But also, I think that there is opportunity out there. We do see a lot of demand for this capacity, otherwise we wouldn't be building it, and certainly see opportunities potentially to have others pay for it, but nothing I could announce right now for sure.
spk05: Understood. Thank you very much.
spk20: Thanks, Matt. Thank you. Our next question comes from the line of Paul Knight with KeyBank. Your line is now open.
spk04: Hi, Nick. Could you talk to the number of customers that you now have and number of products in place as well?
spk03: Good question, Alan. I'll probably best hand that one over to Tim, who's got full detail of that one. But, Tim, do you want to just pick up on the total number of customers?
spk06: You know, I actually don't have a roll-up of the total number of customers. But that does continue to expand every quarter as we announce them and when we're able to announce them quarter by quarter and program by program as well with existing customers.
spk04: And how many are in commercialization, Tim?
spk06: Well, as we, I think, previously disclosed, we have one commercial customer at this point in time.
spk04: Okay.
spk06: And then...
spk04: Nick, based on your long experience in the industry, what gross margin do you believe you should ultimately run at?
spk03: So in terms of adding the new business to our existing capacity, we expect somewhere between 30% and 40% gross margin.
spk04: Okay, and then as you look at these additions at Miford North, Miford South, what do you think you need to do in terms of commercialization talent that you would need to add? Or do you have the talent now?
spk03: So in terms of you're talking about business development to bring in those new opportunities in their lives? Yeah, yeah. I think I expressed this a little bit at the last quarter's call, but I think Tim and the team, and as I did also today, Tim and the team are doing an excellent job. Obviously, we have more insight into leading indicators on the business and the like, but I think as we see it, the team is working extraordinarily well. brought three new clients in as many months in quarter one, another new client this quarter, plus an expansion of an existing client. And as I say, we can see the pipeline going forward, hence the expansion. So I think we've got a team that's more than capable of dealing with the foreseeable future. And we may add to that, but at this moment in time, there's no immediate plans to do so.
spk04: Okay, and then what's your outlook in terms of do you want to go beyond monoclonal antibody manufacturing? Do you envision some of this capacity expansion in other areas like mRNA or cell and gene therapy?
spk03: I think those are always interesting areas, again, kind of from a strategic perspective on my side. First and foremost was to sort of make sure that we sort of looked after our existing client base and made sure that was strong, good relationships. Secondly was to ensure that we have the right infrastructure and people in place to ensure that we execute in a on time, in full, in spec manner for our clients. And then also to have a business development team that we believe can drive the growth. That's kind of been the first, the cornerstones of the strategy for the first period. I think we're moving nicely ahead on that one, and then adding to that the expansion. And then from that point forward, I think the areas that you highlighted are always of interest to maybe consider further expansion of our offering. But again, a little early for us to say anything further than that.
spk04: And then lastly, based on your global experience, how do you feel about a company with the Southern California presence do you have? What are the positives and negatives regarding your presence?
spk03: Yeah. So, I mean, I've run facilities not all over the world, but I think it's about 14 countries the last time I checked. I think it's, as I mentioned again, I think in the last quarter's call, it's a California is a nice place to be right now. I think we're seeing quite a lot of domestication of supply chains of late, COVID adding to the need to do that. We've seen localization rather than globalization as an outsourcing strategy amongst many of the pharmaceutical companies. In fact, in some cases, even We've seen regional purchasing by some people who literally want to stay on the West Coast and not move to the East or vice versa. So if I look at the U.S. market, it's probably the strongest market in the world in terms of farmer development. The California corridor is a very strong component of that overall market. So I think being in Southern California is not a bad place to be right now. So very happy with this as a location.
spk04: Thank you.
spk19: Go light. Go grand. Keeps you going.
spk03: Thanks, Paul.
spk20: Thank you. Our next question comes from the line of Jacob Johnson with Stevens. Your line is now open.
spk02: Hey, thanks, and I'll add my congrats on a really nice quarter. Maybe first, Nick, following up on Paul's last question and on high-level strategy, if we think, as you're thinking about AVID longer term, At some point, could Avid have a presence, you know, beyond Southern California, or how should we think about that?
spk03: Yeah, I think it's more than possible. I think, you know, we do have a global market. Europe and Asia are both very active markets, and if we've got a successful formula, then there's no reason why we shouldn't want to market that capability to a broader base of clients that Ultimately, at the end of the day, custom manufacture does benefit from some degree of localization and being close to your client in terms of project execution and transfer. So a broader geographic spread would not be out of the question from my thinking, as equally a broader offering fulfilling some of the areas that maybe we don't fulfill today. So... Again, first and foremost was to make sure that we got what we're doing well honed, get the expansion moving, and then we can start to look at other things where we feel we can bring value.
spk02: Got it. That makes sense. And maybe kind of a follow-up on it, you know, tied to COVID. I think COVID's highlighted the value of U.S. pharma manufacturing, and I think maybe in coming years we could see somewhat of an insourcing of of drug manufacturing back into the U.S.? You know, is this something that Avid could benefit from at some point?
spk03: I'd like to think so, yeah. I mean, I think we've seen this happening before COVID. So even in small molecules, to be frank with you, we've seen a lot of molecules coming back from Asia, back to Western manufacturers for a variety of reasons. And so I Obviously, in terms of large molecules or biologics, I don't think anywhere near as much of the manufacturing has gone abroad as it did in small molecules. But we'd already seen that trend coming back. I think politically, we'd seen a strong push towards more localized supply. And then COVID on top of that, I think, has made everybody very much aware of the risks and the frailties sometimes global supply chains can have. And so I do think that we will likely benefit from that in the foreseeable future.
spk02: Great. And then I hope so, too. Maybe just a last one for Dan. You know, looking at guidance, I think it implies kind of a weaker back half versus what was a really strong first half. And certainly, as you called out, we're living in an uncertain environment. But In terms of puts and takes, just one thing I wanted to ask about, I think last quarter you got a fee for some unused reserve capacity. I think that might have been for the third quarter. Is that something that could be a bit of a headwind next quarter? And maybe if Tim wants to chime in, just any comments on the effort to maybe backfill and fulfill that capacity?
spk06: Yeah, Jacob, thanks for the question. I think what I'd start with is we initially thought it'd be a little bit of a headwind when we exited the first quarter. Looking at the pipeline and our visibility into our customers, essentially the demand that we're seeing and the backlog that we have in the books, we did have some puts and takes. We had The $3 million that was for the one-time fee, and additionally, we had 1.7 this quarter. It helped out the first half of the year. But, you know, looking at what we can see as far as the visibility into the backlog and our customer demand and where the first half ended up, that's how we got to the $84 to $88 million for the full-year guide.
spk02: Great. Thanks for taking the questions.
spk20: Thank you. This concludes today's question and answer session. I will now hand the call back to Nick Green for closing remarks.
spk03: Thank you, Operator, and thank you to everyone participating on today's call. In closing, I'd like to thank all our employees at AVID. Not only have they been effective and efficient in improving the business performance, but they continue to do this in a challenging environment as a result of COVID-19. AVID's success is dependent upon our incredible employees, and I wish to thank them for their continued efforts in adapting to the challenges which are impacting both their professional but also their personal lives. Thank you again for participating on today's call and for your continued support of AVID Bioservices.
spk20: Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.
Disclaimer